- Patients
- Clinical Research
- Clinical trials
- Beigene BGB-11417-203
2024-02-13T00:00:00.000+11:00
Ongoing
Beigene BGB-11417-203
Beigene BGB-11417-203
Waldenström’s Macroglobulinemia
An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of BCL2 Inhibitor BGB-11417 in Patients With Relapsed/Refractory Waldenström’s Macroglobulinemia
An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of BCL2 Inhibitor BGB-11417 in Patients With Relapsed/Refractory Waldenström’s Macroglobulinemia
Trial overview
Clinical Area
Haematology
Disease / Condition
Waldenström’s Macroglobulinemia
Phase
II
GenesisCare Location(s)
GenesisCare North Shore
GenesisCare North Shore
:::
Principal Investigator(s)